FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1624-1629 June 20, 1996 Number 25 Next

	Full Text PDF Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Patients who have bleeding from esophageal varices are at high risk for rebleeding and death. We compared the efficacy and safety of endoscopic sclerotherapy with the efficacy and safety of nadolol plus isosorbide mononitrate for the prevention of variceal rebleeding.

Methods Eighty-six hospitalized patients with cirrhosis and bleeding from esophageal varices diagnosed by endoscopy were randomly assigned to treatment with repeated sclerotherapy (43 patients) or nadolol plus isosorbide-5-mononitrate (43 patients). The primary outcomes were rebleeding, death, and complications. The hepatic venous pressure gradient was measured at base line and after three months.

Results Base-line data were similar in the two groups, and the median follow-up was 18 months in both. Eleven patients in the medication group and 23 in the sclerotherapy group had rebleeding. The actuarial probability of remaining free of rebleeding was higher in the medication group for all episodes related to portal hypertension (P = 0.001) and variceal rebleeding (P = 0.002). Four patients in the medication group and nine in the sclerotherapy group died (P = 0.07 for the difference in the actuarial probability of survival). Seven patients in the medication group and 16 in the sclerotherapy group had treatment-related complications (P = 0.03). Thirty-one patients in the medication group underwent two hemodynamic studies; 1 of the 13 patients with more than a 20 percent decrease in the hepatic venous pressure gradient had rebleeding, as compared with 8 of the 18 with smaller decreases in the pressure gradient (P = 0.04 for the actuarial probability of rebleeding at two years).

Conclusions As compared with sclerotherapy, nadolol plus isosorbide mononitrate significantly decreased the risk of rebleeding from esophageal varices.

Source Information

From the Department of Gastroenterology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Address reprint requests to Dr. Balanzó at the Servei de Patologia Digestiva, Hospital de la Santa Creu i Sant Pau, Avgda. Sant Antoni M. Claret, 167, 08025 Barcelona, Spain.

Full Text of this Article

This article has been cited by other articles:

• Zipprich, A., Loureiro-Silva, M. R., D'Silva, I., Groszmann, R. J. (2008). The role of hepatic arterial flow on portal venous and hepatic venous wedged pressure in the isolated perfused CCl4-cirrhotic liver. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G197-G202 [Abstract] [Full Text]  
• Groszmann, R. J., Garcia-Tsao, G., Bosch, J., Grace, N. D., Burroughs, A. K., Planas, R., Escorsell, A., Garcia-Pagan, J. C., Patch, D., Matloff, D. S., Gao, H., Makuch, R., the Portal Hypertension Collaborative Group, (2005). Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis.. NEJM 353: 2254-2261 [Abstract] [Full Text]  
• Thalheimer, U, Mela, M, Patch, D, Burroughs, A K (2004). Monitoring target reduction in hepatic venous pressure gradient during pharmacological therapy of portal hypertension: a close look at the evidence. Gut 53: 143-148 [Abstract] [Full Text]  
• Mandell, M. S., Durham, J., Kumpe, D., Trotter, J. F., Everson, G. T., Niemann, C. U. (2003). The Effects of Desflurane and Propofol on Portosystemic Pressure in Patients with Portal Hypertension. Anesth. Analg. 97: 1573-1577 [Abstract] [Full Text]  
• Villanueva, C., Minana, J., Ortiz, J., Gallego, A., Soriano, G., Torras, X., Sainz, S., Boadas, J., Cusso, X., Guarner, C., Balanzo, J. (2001). Endoscopic Ligation Compared with Combined Treatment with Nadolol and Isosorbide Mononitrate to Prevent Recurrent Variceal Bleeding. NEJM 345: 647-655 [Abstract] [Full Text]  
• Sharara, A. I., Rockey, D. C. (2001). Gastroesophageal Variceal Hemorrhage. NEJM 345: 669-681 [Full Text]  
• Pomier-Layrargues, G, Villeneuve, J-P, Deschenes, M, Bui, B, Perreault, P, Fenyves, D, Willems, B, Marleau, D, Bilodeau, M, Lafortune, M, Dufresne, M-P (2001). Transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic variceal ligation in the prevention of variceal rebleeding in patients with cirrhosis: a randomised trial. Gut 48: 390-396 [Abstract] [Full Text]  
• Jalan, R, Hayes, P C (2000). UK guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut 46: iii1-15 [Full Text]  
• Luca, A., D'Amico, G., La Galla, R., Midiri, M., Morabito, A., Pagliaro, L. (1999). TIPS for Prevention of Recurrent Bleeding in Patients with Cirrhosis: Meta-analysis of Randomized Clinical Trials. Radiology 212: 411-421 [Abstract] [Full Text]  
• Patch, D, Armonis, A, Sabin, C, Christopoulou, K, Greenslade, L, McCormick, A, Dick, R, Burroughs, A K (1999). Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 44: 264-269 [Abstract] [Full Text]